Airfinity wins Financial Times’ Tech Champions 2023

Posted on Nov 15, 2023

Airfinity is proud to announce it has been selected as the winning company of the Financial Times’ Tech Champions 2023, in the healthcare category.

The award was looking for tech companies which have risen to the challenges and opportunities presented by new global risks, economic headwinds, geopolitical crises and disruptive AI.

At the forefront of innovation in life sciences, Airfinity tracks, predicts and simulates population level disease outcomes in real time. Our aim is to use data to help leaders make better informed decisions that can increase the global life span.

The awards highlighted Airfinity’s work during the COVID-19 pandemic, on forecasting the ‘tripledemic’ impact of COVID, flu and RSV on healthcare systems, as well as our global surveillance of infectious diseases and our new team analyzing the breakthrough obesity drug market. 

Airfinity’s CEO and founder Rasmus Bech Hansen says, “I am grateful to the Financial Times for this award and for telling part of my own personal story in today’s profile. 

“As Sir John Bell puts it in the article Airfinity delivered ‘Probably the most expansive, accurate and helpful of the multiple data sets on an international scale’ during the pandemic, something the team can rightly be proud of.

“Importantly, a recognition like this helps attract the talent and partners needed to go much further. Global health challenges cannot be solved without better data. Just like an individual needs the right diagnosis and cure, the entire population needs big data and analytics for effective diagnosis on a larger scale.”

Real the Financial Times’ Tech Champion 2023 company profile here

The full list of winners, categories and other shortlisted companies can be read in the special report here

More Insights From Airfinity

Introducing Airfinity Biorisk: Risk Surveillance and Analytics for 160+ Infectious Diseases

Oct 10, 2022

18 million monkeypox vaccines needed to protect most at risk, 85 million to protect wider gay community and health workers

Aug 25, 2022

Sales of COVID-19 antiviral pill Paxlovid to leap frog Merck’s competitor Molnupiravir

Jul 25, 2022

COVID-19 vaccines sales to bounce back with new jabs taking a fifth of the 2022 market

Jul 15, 2022

AstraZeneca and Pfizer/BioNTech saved over 12 million lives in the first year of vaccination

Jul 13, 2022

Global wastage of COVID-19 vaccines could be 1.1 billion doses

Jul 11, 2022